Global Rubella Treatment Market – Industry Trends and Forecast to 2029

Rubella Treatment Market Analysis and Size

The global rubella treatment market is expected to witness significant growth during the forecast period. Growing occurrences of rubella is a direct consequence of the high transmission ability of togavirus through air. Rubella infection usually affects children and adults. The disease has severe effects on pregnant women, leading to fetal death or congenital defects. As per the World Health Organization records, 168 out of 194 countries introduced rubella vaccines in their health programs, and the global coverage was around 69 % as of December 2018. COVID-19 also had a major impact on the market growth.

 Data Bridge Market Research analyses a growth rate in the rubella treatment market in the forecast period 2022-2029. The expected CAGR of rubella treatment market is tend to be around 6.50% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Rubella Treatment Market Scope and Segmentation

Market Definition

Rubella is also known as German measles and is a contagious viral infection caused by rubivirus infection. Rubella is typically characterized by rash, fever and eye redness and is usually found in children. It spreads through air or in contact with the infected person. Rubella infection commonly affects children and adults. The infection has severe implications in pregnant women, that can lead to fetal death or congenital defects. 

Global Rubella Treatment Market Dynamics

Drivers

• Increased Demand of Diagnostic Tests

Diagnostic tests such as flow cytometry, monoclonal antibodies, immunoassays, latex slide agglutination test, serological testing, and clinical evaluation are boosting the growth of the market. These tests are characteristically prescribed for pregnant women and also for women planning to conceive. These tests may also be conducted for babies having congenital defects. Thus, it boosts the market growth.

• Growing Government Initiatives 

Numerous government initiatives relating to research and development of advanced diagnostic techniques in developing countries such as China and India are performed, which is anticipated to boost the market growth in the near future. This boost the growth of the market.

Opportunities

• Rising Demand of MMR Vaccines

Growing demand for measles, mumps and rubella (MMR) vaccines for the protection of children against rubella and the launch of advanced point-of-care diagnostic technologies such as BioPlex 2200 MMRV (varicella zoster, rubella, mumps and measles virus) by Bio Rad Laboratories are moreover creating growth opportunities for the global rubella market.

• Increasing Demand for Retail Pharmacies

The rise in the number of perinatal infections therapeutics delivered through retail pharmacies and more retail pharmacies in developed countries create opportunities for the market expansion. Additionally, patients choose retail pharmacies over other types for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of appropriate healthcare professionals who cannot treat the patients with suitable treatments could curb the growth of the global rubella treatment market over a forecast period.

• Unavailability of Vaccinations

There is wide unavailability of vaccines that is hampering the market growth. Vaccination for rubella are not available in these regions. It was recorded that Thailand, Timor Leste, Macedonia, Tajikistan, and Syria are accounted for biggest number of rubella infection cases as of 2013 but there was lack of vaccines and medicines that hampered the market growth.

This global rubella treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global rubella treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Rubella Treatment Market Scope

The global rubella treatment market is segmented on the basis of drugs, vaccines, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Paracetamol
• Ibuprofen
• Aspirin
• Others

Treatment

• Medication
• Vaccinations

Vaccines

• Proquad
• M-M-R II
• Others

Route of Administration

• Oral
• Injectable

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Rubella Treatment Market Regional Analysis/Insights

The global rubella treatment market is analyzed and market size insights and trends are provided by drugs, vaccines, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global rubella treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing positive growth for global rubella treatment market throughout the forecasted period due to the rising adoption of modern healthcare technologies and initiative the federal government took to promote awareness.

Asia-Pacific dominates the market due to rising expenditure to develop healthcare infrastructure, the presence of untapped opportunities and increasing personal disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Rubella Treatment Market Share Analysis

The global rubella treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global rubella treatment market

Key players operating in the global rubella treatment market include:

• Merck KGaA (Germany)
• Novartis AG (U.S.)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• GSK plc (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• AstraZeneca (U.K.)
• Lilly (U.S.)

SKU-47806